Device-Related Thrombus After Left Atrial Appendage Closure: Data on Thrombus Characteristics, Treatment Strategies, and Clinical Outcomes From the EUROC-DRT-Registry.


Journal

Circulation. Cardiovascular interventions
ISSN: 1941-7632
Titre abrégé: Circ Cardiovasc Interv
Pays: United States
ID NLM: 101499602

Informations de publication

Date de publication:
05 2021
Historique:
entrez: 18 5 2021
pubmed: 19 5 2021
medline: 16 10 2021
Statut: ppublish

Résumé

Left atrial appendage closure is an established therapy in patients with atrial fibrillation. Although device-related thrombosis (DRT) is relatively rare, it is potentially linked to adverse events. As data on DRT characteristics, outcome, and treatment regimen are scarce, we aimed to assess these questions in a multicenter approach. One hundred fifty-six patients with the diagnosis of DRT after left atrial appendage closure were included in the multinational EUROC-DRT registry. Baseline characteristics included clinical and echocardiographic data. After inclusion, all patients underwent further clinical and echocardiographic follow-up to assess DRT dynamics, treatment success, and outcome. DRT was detected after a median of 93 days (interquartile range, 54–161 days) with 17.9% being detected >6 months after left atrial appendage closure. Patients with DRT were at high ischemic and bleeding risk (CHA2DS2-VASc 4.5±1.7, HAS-BLED 3.3±1.2) and had nonparoxysmal atrial fibrillation (67.3%), previous stroke (53.8%), and spontaneous echo contrast (50.6%). The initial treatment regimens showed comparable resolution rates (antiplatelet monotherapy: 57.1%, dual antiplatelet therapy: 85.7%, vitamin K antagonists: 80.0%, novel oral anticoagulants: 75.0%, and heparin: 68.6%). After intensification or switch of treatment, complete DRT resolution was achieved in 79.5% of patients. Two-year follow-up revealed a high risk of mortality (20.0%) and ischemic stroke (13.8%) in patients with DRT. Patients with incomplete DRT resolution showed numerically higher stroke rates and increased mortality rates (stroke: 17.6% versus 12.3%, P=0.29; mortality: 31.3% versus 13.1%, P=0.05). A substantial proportion of DRT is detected >6 months after left atrial appendage closure, highlighting the need for imaging follow-up. Patients with DRT appear to be at a high risk for stroke and mortality. While DRT resolution was achieved in most patients, incomplete DRT resolution appeared to identify patients at even higher risk. Optimal DRT diagnostic criteria and treatment regimens are warranted.

Sections du résumé

BACKGROUND
Left atrial appendage closure is an established therapy in patients with atrial fibrillation. Although device-related thrombosis (DRT) is relatively rare, it is potentially linked to adverse events. As data on DRT characteristics, outcome, and treatment regimen are scarce, we aimed to assess these questions in a multicenter approach.
METHODS
One hundred fifty-six patients with the diagnosis of DRT after left atrial appendage closure were included in the multinational EUROC-DRT registry. Baseline characteristics included clinical and echocardiographic data. After inclusion, all patients underwent further clinical and echocardiographic follow-up to assess DRT dynamics, treatment success, and outcome.
RESULTS
DRT was detected after a median of 93 days (interquartile range, 54–161 days) with 17.9% being detected >6 months after left atrial appendage closure. Patients with DRT were at high ischemic and bleeding risk (CHA2DS2-VASc 4.5±1.7, HAS-BLED 3.3±1.2) and had nonparoxysmal atrial fibrillation (67.3%), previous stroke (53.8%), and spontaneous echo contrast (50.6%). The initial treatment regimens showed comparable resolution rates (antiplatelet monotherapy: 57.1%, dual antiplatelet therapy: 85.7%, vitamin K antagonists: 80.0%, novel oral anticoagulants: 75.0%, and heparin: 68.6%). After intensification or switch of treatment, complete DRT resolution was achieved in 79.5% of patients. Two-year follow-up revealed a high risk of mortality (20.0%) and ischemic stroke (13.8%) in patients with DRT. Patients with incomplete DRT resolution showed numerically higher stroke rates and increased mortality rates (stroke: 17.6% versus 12.3%, P=0.29; mortality: 31.3% versus 13.1%, P=0.05).
CONCLUSIONS
A substantial proportion of DRT is detected >6 months after left atrial appendage closure, highlighting the need for imaging follow-up. Patients with DRT appear to be at a high risk for stroke and mortality. While DRT resolution was achieved in most patients, incomplete DRT resolution appeared to identify patients at even higher risk. Optimal DRT diagnostic criteria and treatment regimens are warranted.

Identifiants

pubmed: 34003661
doi: 10.1161/CIRCINTERVENTIONS.120.010195
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e010195

Auteurs

Alexander Sedaghat (A)

University Hospital Bonn, Germany (A.S., V.V., B.A.-K., J.W.S., G.N.).

Vivian Vij (V)

University Hospital Bonn, Germany (A.S., V.V., B.A.-K., J.W.S., G.N.).

Baravan Al-Kassou (B)

University Hospital Bonn, Germany (A.S., V.V., B.A.-K., J.W.S., G.N.).

Steffen Gloekler (S)

University Hospital Bern, Switzerland (S.G., R.G., M.F., B.M., M.V.).

Roberto Galea (R)

University Hospital Bern, Switzerland (S.G., R.G., M.F., B.M., M.V.).

Monika Fürholz (M)

University Hospital Bern, Switzerland (S.G., R.G., M.F., B.M., M.V.).

Bernhard Meier (B)

University Hospital Bern, Switzerland (S.G., R.G., M.F., B.M., M.V.).

Marco Valgimigli (M)

University Hospital Bern, Switzerland (S.G., R.G., M.F., B.M., M.V.).
Cardiocentro Ticino, Lugano, Switzerland (M.V.).

Gilles O'Hara (G)

Quebec Heart & Lung Institute, Laval University, Canada (G.O., L.A., J.R.-C.).

Dabit Arzamendi (D)

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (D.A., V.A., L.A.).

Victor Agudelo (V)

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (D.A., V.A., L.A.).

Lluis Asmarats (L)

Quebec Heart & Lung Institute, Laval University, Canada (G.O., L.A., J.R.-C.).
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain (D.A., V.A., L.A.).

Xavier Freixa (X)

Hospital Clinic Barcelona, Spain (X.F., E.F.-U.).

Eduardo Flores-Umanzor (E)

Hospital Clinic Barcelona, Spain (X.F., E.F.-U.).

Ole De Backer (O)

Rigshospitalet Copenhagen University Hospital, Denmark (O.D.B., L.S.).

Lars Søndergaard (L)

Rigshospitalet Copenhagen University Hospital, Denmark (O.D.B., L.S.).

Luis Nombela-Franco (L)

Hospital Clinico San Carlos Madrid, Spain (L.N.-F., A. McInerney).

Angela McInerney (A)

Hospital Clinico San Carlos Madrid, Spain (L.N.-F., A. McInerney).

Kaspar Korsholm (K)

University Hospital Aarhus, Denmark (K.K., J.E.N.-K.).

Jens Erik Nielsen-Kudsk (JE)

University Hospital Aarhus, Denmark (K.K., J.E.N.-K.).

Shazia Afzal (S)

University Hospital Düsseldorf, Germany (S.A., T.Z.).

Tobias Zeus (T)

University Hospital Düsseldorf, Germany (S.A., T.Z.).

Felix Operhalski (F)

Agaplesion Bethanien Krankenhaus, CBB, Frankfurt, Germany (F.O., B.S.).

Boris Schmidt (B)

Agaplesion Bethanien Krankenhaus, CBB, Frankfurt, Germany (F.O., B.S.).

Gilles Montalescot (G)

Surbonne University Pitié-Salpêtrière Hospital (AP-HP) Paris, France (G.M., P.G.).

Paul Guedeney (P)

Surbonne University Pitié-Salpêtrière Hospital (AP-HP) Paris, France (G.M., P.G.).

Xavier Iriart (X)

University Hospital Bordeaux, France (X.I., N.M.).

Noelie Miton (N)

University Hospital Bordeaux, France (X.I., N.M.).

Jacqueline Saw (J)

Vancouver General Hospital, Vancouver, Canada (J.S.).

Thomas Gilhofer (T)

Stadtspital Waid and Triemli, Zürich, Switzerland (T.G.).

Laurent Fauchier (L)

University Hospital Tours, France (L.F.).

Egzon Veliqi (E)

St. Georg Hospital Hamburg, Germany (E.V., F.M.).

Felix Meincke (F)

St. Georg Hospital Hamburg, Germany (E.V., F.M.).

Nils Petri (N)

University Hospital Würzburg, Germany (N.P., P.N.).

Peter Nordbeck (P)

University Hospital Würzburg, Germany (N.P., P.N.).

Szymon Rycerz (S)

Schwarzwald-Baar Klinikum, Villingen-Schwenningen, Germany (S.R.).

Dmitrii Ognerubov (D)

Russian Cardiology Research and Production Complex, Moscow (D.O., E.M.).

Evgeny Merkulov (E)

Russian Cardiology Research and Production Complex, Moscow (D.O., E.M.).

Ignacio Cruz-González (I)

University Hospital of Salamanca, CIBER CV, IBSAL, Spain (I.C.-G., R.G.-F.).

Rocio Gonzalez-Ferreiro (R)

University Hospital of Salamanca, CIBER CV, IBSAL, Spain (I.C.-G., R.G.-F.).

Deepak L Bhatt (DL)

Heart and Vascular Center, Brigham and Women's Hospital Harvard Medical School, Boston (D.L.B.).

Alessandra Laricchia (A)

Maria Cecilia Hospital Cotignola, Italy (A.L., A. Mangieri).

Antonio Mangieri (A)

Maria Cecilia Hospital Cotignola, Italy (A.L., A. Mangieri).

Heyder Omran (H)

Marienkrankenhaus, Bonn, Germany (H.O.).

Jan Wilko Schrickel (JW)

University Hospital Bonn, Germany (A.S., V.V., B.A.-K., J.W.S., G.N.).

Josep Rodes-Cabau (J)

Quebec Heart & Lung Institute, Laval University, Canada (G.O., L.A., J.R.-C.).

Georg Nickenig (G)

University Hospital Bonn, Germany (A.S., V.V., B.A.-K., J.W.S., G.N.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH